Nurix Therapeutics Stock Rises Following Major Drug Development Agreement with Roche

Nurix Therapeutics experienced a significant stock increase after entering a substantial partnership with Roche. The agreement involves Roche acquiring rights to an experimental blood-cancer drug, with potential payments reaching $2.3 billion. This collaboration highlights a major development in the biopharmaceutical sector for a clinical-stage company.